More MS news articles for June 2003

Live Internet chat with experts on 20 June

http://www.mssociety.org.uk/a_chance_to_talk/chats_talks/20_june_chat.html

June, 2003
Multiple Sclerosis Society

Dr Alasdair Coles, Professor David Miller and Dr John Zajicek will answer your questions on advances in MS treatments on 20 June from 2-5pm. Please note the time slots for each speaker.

2pm: Dr John Zajicek

Dr Zajicek is currently a Reader in Neurology with the Peninsula Medical School, and Honorary Consultant at Derriford Hospital in Plymouth. He has a background in cell biology and immunology whilst working in Cambridge, and then moved into more clinical surroundings when he joined the Plymouth team in 1995. Since then he has been actively involved in developing neurology services and is one of the lead investigators in the Cannabinoids in MS (CAMS) trial. He is currently involved in a number of other clinical trials relating to MS and is very optimistic that clinical research will produce treatments for MS in the near future.

3pm: Professor David Miller

David Miller is Professor of Clinical Neurology at the Institute of Neurology and Honorary Consultant Neurologist at the National Hospital for Neurology and Neurosurgery. His major clinical and research interests are multiple sclerosis and magnetic resonance imaging. He is Head of the Department of Neuroinflammation and is a joint leader of the Multiple Sclerosis/NMR Research Unit at the Institute of Neurology. This research group has been active in the last 16 years using MR imaging and spectroscopy to improve the accuracy of diagnosis of MS; identify MR measures to predict the future course; improve understanding of the mechanisms of disability and recovery, and monitor new treatments.

4pm: Dr Alasdair Coles

Alasdair Coles is an academic neurologist in Cambridge, working on experimental therapies for multiple sclerosis. Alasdair is the Wellcome Advanced Fellow of Neurology at Addensbrookes Hospital, Cambridge. In particular, he is associated with the development the use of a monoclonal antibody called Campath-1H in multiple sclerosis. His laboratory work involves studying the effects of these therapies on the immune systems of people with multiple sclerosis.

See the MS Society chat index page at:
http://www.mssociety.org.uk/a_chance_to_talk/chats_talks/index.html

If you have any questions about this chat event please contact the Webteam